Last reviewed · How we verify
MMC in Trabeculectomy
MMC in Trabeculectomy is a Alkylating agent / Antimetabolite Small molecule drug developed by Pro Top & Mediking Company Limited. It is currently in Phase 3 development for Adjunctive use in trabeculectomy for primary open-angle glaucoma, Adjunctive use in trabeculectomy for secondary glaucomas.
Mitomycin C (MMC) is an alkylating agent that inhibits fibroblast proliferation and collagen synthesis to prevent scarring during trabeculectomy surgery.
Mitomycin C (MMC) is an alkylating agent that inhibits fibroblast proliferation and collagen synthesis to prevent scarring during trabeculectomy surgery. Used for Adjunctive use in trabeculectomy for primary open-angle glaucoma, Adjunctive use in trabeculectomy for secondary glaucomas.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MMC in Trabeculectomy |
|---|---|
| Sponsor | Pro Top & Mediking Company Limited |
| Drug class | Alkylating agent / Antimetabolite |
| Target | DNA cross-linking agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
MMC is applied topically during trabeculectomy (glaucoma filtration surgery) to suppress fibroblast activity and reduce postoperative scarring of the surgical site. By limiting scar tissue formation, MMC helps maintain the patency of the drainage bleb and improves long-term surgical success rates. This mechanism is particularly important in high-risk patients prone to excessive wound healing.
Approved indications
- Adjunctive use in trabeculectomy for primary open-angle glaucoma
- Adjunctive use in trabeculectomy for secondary glaucomas
Common side effects
- Corneal toxicity / epithelial defects
- Hypotony (low intraocular pressure)
- Bleb-related infections
- Cataract progression
Key clinical trials
- Preserflo MicroShunt Versus Trabeculectomy (NA)
- Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma (NA)
- SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients (NA)
- Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT (NA)
- Electron Microscopic Examination of Iris Tissue in Buphthalmos (NA)
- Sponge Application of MMC Versus Suntenon Injection in Trabeculectomy (NA)
- Analysis of Conjunctival Changes as Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes (NA)
- Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMC in Trabeculectomy CI brief — competitive landscape report
- MMC in Trabeculectomy updates RSS · CI watch RSS
- Pro Top & Mediking Company Limited portfolio CI
Frequently asked questions about MMC in Trabeculectomy
What is MMC in Trabeculectomy?
How does MMC in Trabeculectomy work?
What is MMC in Trabeculectomy used for?
Who makes MMC in Trabeculectomy?
What drug class is MMC in Trabeculectomy in?
What development phase is MMC in Trabeculectomy in?
What are the side effects of MMC in Trabeculectomy?
What does MMC in Trabeculectomy target?
Related
- Drug class: All Alkylating agent / Antimetabolite drugs
- Target: All drugs targeting DNA cross-linking agent
- Manufacturer: Pro Top & Mediking Company Limited — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Adjunctive use in trabeculectomy for primary open-angle glaucoma
- Indication: Drugs for Adjunctive use in trabeculectomy for secondary glaucomas
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing